Yi An, MD
Associate Professor of Therapeutic RadiologyCards
About
Research
Publications
2024
Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
Moningi S, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Taplin M, Kollmeier M, Hoffman K. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e563-e564. DOI: 10.1016/j.ijrobp.2024.07.1247.Peer-Reviewed Original ResearchMonths of GnRH agonistTestosterone recoveryGnRH agonistAssociated with lackClinically meaningful changeBaseline testosteroneAssociated with testosterone recoveryMedian Follow-UpEvaluated prior to treatmentTreatment groupsTrial randomized patientsHormonal functionPatient-reported health-related quality of lifeLog-rank testCompletion of treatmentMultivariate logistic regressionWilcoxon rank-sumPatient-reported HRQoL.Salvage radiationGleason scoreAbiraterone acetateHigher PSARecovery 1 yearRandomized patientsHealth-related quality of lifeLong-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
Hoffman K, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Lee K, Kibel A, Taplin M, Kollmeier M. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s54. DOI: 10.1016/j.ijrobp.2024.07.088.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneMonths of GnRH agonistAcetate plus prednisonePatient-reported health-related quality of lifeEPIC-26Hormonal functionHealth-related quality of lifeGnRH agonistTreatment armsTreatment to 1 yearQuality of lifeMental statusMetastasis-free survivalBaseline to endCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesRadical prostatectomyClinically meaningful differencesSaint Louis University Mental Status ExamNear baselineClinically meaningful declineT-scoreHormonal domainsAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024, 8: 1101-1110. PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage dataSynthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells
Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong S, Link T, Gallup T, Qie Y, Li X, Dong S, Schrank B, Grippin A, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong A, Tainer J, Jiang W, Kim B. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering 2024, 8: 593-610. PMID: 38641710, PMCID: PMC11162332, DOI: 10.1038/s41551-024-01194-7.Peer-Reviewed Original ResearchAntigen-presenting cellsInnate immune pathwaysImmune pathwaysPriming of effector T cellsImmune checkpoint inhibitorsAntitumour immune responseEffector T cellsIntracellular DNA-sensing pathwaysMetastatic breast cancerSyngeneic mouse modelMultiple innate immune pathwaysAdaptive immunogenicityAntitumour responseCheckpoint inhibitorsEndoplasmic reticulum stressT cellsSystemic clearanceBreast cancerDNA-sensing pathwayRelease of mitochondrial DNATherapeutic advantageMouse modelImmune responseEfficient primingIntracellular deliveryPatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differences
2023
Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective Study
Mange A, Singh C, Theriault B, Hansen J, An Y, Aneja S, Chiang V. Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e135. DOI: 10.1016/j.ijrobp.2023.06.939.Peer-Reviewed Original ResearchMultiple brain metastasesBrain metastasesStereotactic radiosurgeryMedian KPSCommon indicationTumor characteristicsClinical trialsSRS treatmentSingle-institution retrospective studySubsequent-line treatmentMethods Clinical dataPatient selection criteriaTreatment of patientsSubset of lesionsNumber of lesionsDiagnosis of melanomaCNS progressionCNS radiationPrior WBRTOverall survivalPalliative treatmentPatient characteristicsProgressive diseaseImmunotherapy trialsSurvival groupFORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s81-s82. DOI: 10.1016/j.ijrobp.2023.06.401.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyGnRH agonistPre-planned analysisPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian Follow-UpSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitTwo-sided p-valuePelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse eventsMP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET
Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.Peer-Reviewed Original ResearchMP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE
Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
HIC ID2000027702RoleSub InvestigatorPrimary Completion Date10/01/2025Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Yi An, MD, is a radiation oncologist in the Department of Therapeutic Radiology at Yale Medicine. He specializes in treating head and neck, gastrointestinal, prostate and lung cancers.
“I am so fortunate to have the privilege of taking care of cancer patients,”
Dr. An says. “Every day, I have the special opportunity to get to know and form lasting relationships with my patients.” Dr. An is trained in modern radiation treatment techniques, including intensity-modulated radiation therapy, stereotactic body radiation therapy and stereotactic radiosurgery. These cutting-edge radiation techniques, Dr. An says, can target and destroy cancer cells while also minimizing radiation doses to normal tissue and reduce the risk of side effects of treatment.
“Being with my patients at perhaps their most trying time in life,” he says, “drives me to do everything possible to cure their disease and alleviate their pain.”
At Yale School of Medicine, Dr. An is an assistant professor of therapeutic radiology.
Clinical Specialties
Prostate & Genitourinary Radiotherapy; Urologic Oncology; Neuro-Oncology
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineMetastatic Brain Tumors
Learn More on Yale MedicineRhabdomyosarcoma
Learn More on Yale Medicine
Yale Medicine News
News
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Clinical Inquiry Number
Office Fax Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Apr 202611Saturday
Everyone David A. Braun, MD, PhD - Fed Ghali, MD - Kimberly L. Johung, MD, PhD - Harriet Kluger, MD - Yi An, MD - Veda Giri, MD - Michael Hurwitz, MD, PhD - Patrick A. Kenney, MD - David Schoenfeld, MD, PhD - Muneeb Alam, MD